STOCK-BASED COMPENSATION AND EMPLOYEE BENEFIT PLANS	6 Months Ended
Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation and Employee Benefit Plans	STOCK-BASED COMPENSATION AND EMPLOYEE BENEFIT PLANS BioScrip Equity Incentive Plans Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. A total of 16,406,939 shares of Common Stock were initially authorized for issuance under the 2018 Plan, which included the shares that remained available under the 2008 Plan. No key employee in any calendar year will be granted more than 3,000,000 shares of Common Stock with respect to any combination of (i) Options to purchase shares of Common Stock, (ii) Stock Appreciation Rights (based on the appreciation with respect to shares of Common Stock); and (iii) Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code. As of June 30, 2019, there were 13,199,877 shares of Common Stock available for future grant under the 2018 Plan. Stock Options The Company recognized compensation expense related to stock options of $0.2 million and $0.3 million during the three months ended June 30, 2019 and 2018, respectively, and $0.4 million and $0.6 million of compensation expense during the six months ended June 30, 2019 and 2018, respectively. Restricted Stock The Company recognized $0.8 million and $0.8 million of compensation expense related to restricted stock awards during the three months ended June 30, 2019 and 2018, respectively, and $1.6 million and $1.0 million of compensation expense during the six months ended June 30, 2019 and 2018, respectively. Employee Stock Purchase Plan On May 3, 2018, the Company’s stockholders approved an amendment to the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. As of June 30, 2019, there were 1,310,802 remaining shares available for issuance under the ESPP. In July 2019, 73,639 shares were issued to participants under this plan for elections made for the second quarter of 2019. During the three months and six months ended June 30, 2019 and 2018, the Company incurred nominal expense related to the ESPP.

STOCK-BASED COMPENSATION AND EMPLOYEE BENEFIT PLANS

BioScrip Equity Incentive Plans

Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.

A total of 16,406,939 shares of Common Stock were initially authorized for issuance under the 2018 Plan, which included the shares that remained available under the 2008 Plan. No key employee in any calendar year will be granted more than 3,000,000 shares of Common Stock with respect to any combination of (i) Options to purchase shares of Common Stock, (ii) Stock Appreciation Rights (based on the appreciation with respect to shares of Common Stock); and (iii) Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code.

As of June 30, 2019, there were 13,199,877 shares of Common Stock available for future grant under the 2018 Plan.

Stock Options

The Company recognized compensation expense related to stock options of $0.2 million and $0.3 million during the three months ended June 30, 2019 and 2018, respectively, and $0.4 million and $0.6 million of compensation expense during the six months ended June 30, 2019 and 2018, respectively.

Restricted Stock

The Company recognized $0.8 million and $0.8 million of compensation expense related to restricted stock awards during the three months ended June 30, 2019 and 2018, respectively, and $1.6 million and $1.0 million of compensation expense during the six months ended June 30, 2019 and 2018, respectively.

Employee Stock Purchase Plan

On May 3, 2018, the Company’s stockholders approved an amendment to the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period.

As of June 30, 2019, there were 1,310,802 remaining shares available for issuance under the ESPP. In July 2019, 73,639 shares were issued to participants under this plan for elections made for the second quarter of 2019. During the three months and six months ended June 30, 2019 and 2018, the Company incurred nominal expense related to the ESPP.